CY1116925T1 - Ρελαξινη για χρηση στη θεραπευτικη αγωγη της δυσπνοιας η οποια συσχετιζεται με οξεια καρδιακη ανεπαρκεια - Google Patents

Ρελαξινη για χρηση στη θεραπευτικη αγωγη της δυσπνοιας η οποια συσχετιζεται με οξεια καρδιακη ανεπαρκεια

Info

Publication number
CY1116925T1
CY1116925T1 CY20151100824T CY151100824T CY1116925T1 CY 1116925 T1 CY1116925 T1 CY 1116925T1 CY 20151100824 T CY20151100824 T CY 20151100824T CY 151100824 T CY151100824 T CY 151100824T CY 1116925 T1 CY1116925 T1 CY 1116925T1
Authority
CY
Cyprus
Prior art keywords
relaxin
acute heart
acute
heart deficiency
education
Prior art date
Application number
CY20151100824T
Other languages
Greek (el)
English (en)
Inventor
Elaine Unemori
Sam L Teichman
Gad Cotter
Dennis R Stewart
Martha Jo Whitehouse
Original Assignee
Corthera, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corthera, Inc. filed Critical Corthera, Inc.
Publication of CY1116925T1 publication Critical patent/CY1116925T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20151100824T 2008-05-16 2015-09-18 Ρελαξινη για χρηση στη θεραπευτικη αγωγη της δυσπνοιας η οποια συσχετιζεται με οξεια καρδιακη ανεπαρκεια CY1116925T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US19054508P 2008-08-28 2008-08-28
US20124008P 2008-12-08 2008-12-08
US16433309P 2009-03-27 2009-03-27
EP09747740.0A EP2288373B1 (en) 2008-05-16 2009-05-15 Relaxin for use in treating of dyspnea associated with acute heart failure

Publications (1)

Publication Number Publication Date
CY1116925T1 true CY1116925T1 (el) 2017-04-05

Family

ID=40834101

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100824T CY1116925T1 (el) 2008-05-16 2015-09-18 Ρελαξινη για χρηση στη θεραπευτικη αγωγη της δυσπνοιας η οποια συσχετιζεται με οξεια καρδιακη ανεπαρκεια

Country Status (30)

Country Link
US (7) US8415301B2 (enExample)
EP (2) EP2829280A1 (enExample)
JP (4) JP5651586B2 (enExample)
CN (3) CN102036679A (enExample)
AR (1) AR071810A1 (enExample)
AU (1) AU2009246114B2 (enExample)
BR (1) BRPI0913011A2 (enExample)
CA (1) CA2724540C (enExample)
CR (1) CR11749A (enExample)
CY (1) CY1116925T1 (enExample)
DK (1) DK2288373T3 (enExample)
EA (2) EA022948B1 (enExample)
ES (1) ES2546287T3 (enExample)
GB (2) GB2459983B (enExample)
HK (1) HK1202054A1 (enExample)
HR (1) HRP20150845T1 (enExample)
HU (1) HUE025483T2 (enExample)
IL (3) IL208992A (enExample)
MA (1) MA32389B1 (enExample)
MX (1) MX2010012450A (enExample)
MY (2) MY159803A (enExample)
NZ (3) NZ701038A (enExample)
PL (1) PL2288373T3 (enExample)
PT (1) PT2288373E (enExample)
SG (2) SG191587A1 (enExample)
SI (1) SI2288373T1 (enExample)
TW (1) TWI386202B (enExample)
UA (1) UA99953C2 (enExample)
WO (1) WO2009140659A2 (enExample)
ZA (1) ZA201007449B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009246112B2 (en) * 2008-05-16 2013-05-02 Corthera, Inc. Method of treating chronic heart failure
US8415301B2 (en) * 2008-05-16 2013-04-09 Corthera, Inc. Method of treating dyspnea associated with acute heart failure by administering H2 relaxin
KR101800040B1 (ko) * 2010-03-10 2017-11-21 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 릴랙신을 사용한 아쿠아포린의 조절
JP5899213B2 (ja) 2010-08-06 2016-04-06 マイカーティス エヌ．ヴェ．ＭｙＣａｒｔｉｓ ＮＶ 腎機能不全のバイオマーカーとしてのパールカン
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
PE20140160A1 (es) * 2010-08-17 2014-02-08 Ambrx Inc Polipeptidos de relaxina modificados y sus usos
AU2012280474A1 (en) * 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
WO2013059879A1 (en) * 2011-10-26 2013-05-02 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
JP6562632B2 (ja) * 2012-02-14 2019-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 心血管疾患および他の状態のためのパラクリン遺伝子の全身送達および制御された発現
US9452973B2 (en) 2012-05-04 2016-09-27 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Modulators of the relaxin receptor 1
CN110840890A (zh) 2012-10-26 2020-02-28 凯西制药公司 用于在心力衰竭中控制血压和减轻呼吸困难的方法
CN105431145B (zh) 2013-04-05 2019-12-10 Sc医药品有限公司 用于呋塞米的皮下施用的药物制剂
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
HK1226581A1 (zh) * 2014-02-03 2017-09-29 Novartis Ag 用於输液器上的过滤器
EP2946788A1 (en) * 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
JP6820748B2 (ja) * 2014-06-13 2021-01-27 ノバルティス アーゲー Ｇｄｆ−１５を減少させるためのセレラキシンの使用
US11161891B2 (en) 2015-12-09 2021-11-02 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
CN108697330B (zh) 2016-02-12 2022-07-15 心脏起搏器股份公司 用于患者监视的系统和方法
SG10201912034UA (en) 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US11832970B2 (en) 2017-07-26 2023-12-05 Cardiac Pacemakers, Inc. Worsening heart failure stratification
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
ES3041602T3 (en) 2018-12-10 2025-11-13 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
ES3058386T3 (es) 2019-01-04 2026-03-10 Sq Innovation Ag Composiciones farmacéuticas de furosemida
EP3906020B1 (en) 2019-01-04 2025-12-31 SQ Innovation AG Pharmaceutical compositions of torsemide and their uses
AU2020214314B2 (en) 2019-01-31 2025-09-18 Scpharmaceuticals Inc. Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
JP2025528469A (ja) 2022-08-31 2025-08-28 リラクセラ ファルマツォイティッシュ ゲゼルシャフト エムベーハー ウント コー． カーゲー 免疫抑制薬及び処置方法
EP4791358A1 (en) 2023-09-15 2026-08-19 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Relaxin medication
CN121837268B (zh) * 2026-03-12 2026-06-16 西安建筑科技大学 一种基于渐进性风险排序的尘肺病早期精细化筛查方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) * 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
US5478807A (en) 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
CA2165781C (en) 1993-06-21 2007-02-13 Tim Breece Process for producing relaxin
CA2145515A1 (en) * 1993-07-27 1995-02-09 Mario Bigazzi Use of relaxin as therapeutic or preventing agent
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5811395A (en) * 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
ES2187667T3 (es) * 1995-08-15 2003-06-16 Connetics Corp Uso de relaxina para estimular angiogenesis.
ATE362770T1 (de) * 2000-02-09 2007-06-15 Bas Medical Inc Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
DE10155843A1 (de) * 2000-11-16 2003-01-30 Immundiagnostik Ag Verfahren zur Prognose und Diagnose von Herzinsuffizienz
US20050113286A1 (en) 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US7878978B2 (en) * 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
EP1729817B1 (en) * 2004-03-30 2014-03-05 Industry-Academic Cooperation Foundation Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin
US20060264367A1 (en) 2005-05-21 2006-11-23 Howard Florey Institute Prevention of fibrosis following cardiac injury
WO2007008907A2 (en) * 2005-07-11 2007-01-18 Abbott Laboratories Methods for determining how to treat congestive heart failure
CA2693651A1 (en) 2007-07-12 2009-01-15 Ronen Shemesh Bioactive peptides and method of using same
AU2009246112B2 (en) 2008-05-16 2013-05-02 Corthera, Inc. Method of treating chronic heart failure
US8415301B2 (en) * 2008-05-16 2013-04-09 Corthera, Inc. Method of treating dyspnea associated with acute heart failure by administering H2 relaxin

Also Published As

Publication number Publication date
MY159803A (en) 2017-02-15
US20150320834A1 (en) 2015-11-12
IL228244A (en) 2016-10-31
NZ701038A (en) 2016-01-29
PL2288373T3 (pl) 2015-11-30
HK1187550A1 (zh) 2014-04-11
TW200948353A (en) 2009-12-01
EP2288373B1 (en) 2015-06-24
US8053411B2 (en) 2011-11-08
MA32389B1 (fr) 2011-06-01
NZ589009A (en) 2012-05-25
HK1151229A1 (en) 2012-01-27
WO2009140659A3 (en) 2010-07-22
CA2724540A1 (en) 2009-11-19
HK1139051A1 (en) 2010-09-10
GB2459983A (en) 2009-11-18
EP2829280A1 (en) 2015-01-28
GB2462221A (en) 2010-02-03
CN106177914A (zh) 2016-12-07
JP5651586B2 (ja) 2015-01-14
EA022948B1 (ru) 2016-03-31
JP2016053040A (ja) 2016-04-14
BRPI0913011A2 (pt) 2019-09-03
HUE025483T2 (en) 2016-02-29
US9579363B2 (en) 2017-02-28
UA99953C2 (uk) 2012-10-25
ES2546287T3 (es) 2015-09-22
US9066916B2 (en) 2015-06-30
AU2009246114B2 (en) 2013-01-31
US20130116181A1 (en) 2013-05-09
SG191587A1 (en) 2013-07-31
MX2010012450A (es) 2011-03-21
AR071810A1 (es) 2010-07-14
MY158327A (en) 2016-09-30
DK2288373T3 (en) 2015-09-28
SI2288373T1 (sl) 2015-12-31
CR11749A (es) 2011-02-11
CA2724540C (en) 2014-07-08
US20120040903A1 (en) 2012-02-16
TWI386202B (zh) 2013-02-21
IL208992A0 (en) 2011-01-31
US8372809B2 (en) 2013-02-12
HK1202054A1 (en) 2015-09-18
PT2288373E (pt) 2015-10-19
CN102036679A (zh) 2011-04-27
US9205132B2 (en) 2015-12-08
GB0908432D0 (en) 2009-06-24
HK1140693A1 (en) 2010-10-22
US20120040902A1 (en) 2012-02-16
US20130210730A1 (en) 2013-08-15
HRP20150845T1 (hr) 2015-11-06
US8415301B2 (en) 2013-04-09
SG10201609580YA (en) 2016-12-29
IL247351A0 (en) 2016-09-29
WO2009140659A2 (en) 2009-11-19
NZ598709A (en) 2013-09-27
GB2459983B (en) 2010-04-28
EA201500552A1 (ru) 2016-07-29
CN103212063B (zh) 2015-07-22
EP2288373A2 (en) 2011-03-02
EA201001771A1 (ru) 2011-06-30
GB2462221B (en) 2010-09-01
AU2009246114A1 (en) 2009-11-19
JP2015013870A (ja) 2015-01-22
IL208992A (en) 2013-09-30
JP5638044B2 (ja) 2014-12-10
US20100048475A1 (en) 2010-02-25
GB0918132D0 (en) 2009-12-02
JP2011520918A (ja) 2011-07-21
JP2013040174A (ja) 2013-02-28
US20170151311A1 (en) 2017-06-01
ZA201007449B (en) 2011-06-29
CN103212063A (zh) 2013-07-24
JP5875646B2 (ja) 2016-03-02

Similar Documents

Publication Publication Date Title
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
MX2023005455A (es) Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
CY1121041T1 (el) Μεθοδοι αγωγης παιδιατρικων ασθενων με τη χρηση δεξμεδετομιδινης
EA201500552A1 (ru) Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
MX336145B (es) Metodo para el tratamiento de insuficiencia cardiaca cronica.
PH12015500407B1 (en) Methods of treating hypertriglyceridemia
MX391565B (es) Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
EA201991014A1 (ru) Лечение диабета
ZA201804696B (en) Therapeutic use of inhibitors of t cell activation or stimulation
EP3825419A3 (en) Diagnostic, prognostic and therapeutic uses of long noncoding rnas for heart disease and regenerative medicine
CY1116344T1 (el) Κυτταρα προερχομενα απο ιστο ομφαλιου λωρου για την θεραπεια νευροπαθητικου πονου και σπαστικοτητας
EP2582682A4 (en) METHOD FOR THE TREATMENT OF LUNG DISEASES
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
PH12017500392A1 (en) Medical treatments based on anamorelin
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
DK1732551T3 (da) Perhexilin til behandling af kronisk hjertesvigt
EA201200319A1 (ru) Введение активированного угля при оказании неотложной помощи в случае передозировки этексилата дабигатрана
UY31499A1 (es) Nuevo uso medico de las sales de propionato 3- (2,2,2-trimetilhydrazinio) en el trtamiento de la enfermedad cardiaca isquemica
AU2013201629B2 (en) Treating dyspnea associated with acute heart failure with relaxin
WO2013177478A3 (en) Treatment method
CU20100225A7 (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
PH12016500711A1 (en) Method of treating dyspnea associated with acute heart failure
RU2010154218A (ru) Способ лечения поздней кожной порфирии у больного зависимого от гемодиализа
UA109904C2 (uk) Комбінована терапія для шкірних розладів